XEVMPD Guide for Pharmacovigilance Professionals

Introduction

The eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) is one of the least visible yet most important components of the European pharmacovigilance ecosystem.

While pharmacovigilance professionals often focus on adverse event reporting, signal detection and risk management activities, those processes depend heavily upon accurate medicinal product information.

XEVMPD provides the structured product information that supports many regulatory and pharmacovigilance activities within Europe.

Although many QPPVs may never directly enter data into XEVMPD, they are expected to understand how medicinal product information is governed and how data quality issues can affect pharmacovigilance compliance.

What is XEVMPD?

XEVMPD stands for eXtended EudraVigilance Medicinal Product Dictionary.

It is the European database containing structured information relating to medicinal products authorised within the European Economic Area.

The database supports:

• Product identification
• Regulatory reporting
• Pharmacovigilance activities
• Signal detection
• Safety surveillance
• Data consistency

In simple terms:

Together these systems support the wider European pharmacovigilance framework.

Why XEVMPD Exists

Before structured product dictionaries became available, product information was often inconsistent across different systems and organisations.

This created challenges including:

• Duplicate product records
• Inconsistent product naming
• Difficulties linking reports to products
• Reduced analytical capability
• Data quality concerns

A central medicinal product dictionary helps ensure that safety reports can be associated with the correct products and analysed consistently.

What Information is Stored in XEVMPD?

XEVMPD contains structured information relating to medicinal products.

Examples include:

• Product names
• Active substances
• Pharmaceutical forms
• Strengths
• Routes of administration
• Marketing authorisation details
• Marketing status
• Product identifiers

The precise data model is considerably more complex, but these examples illustrate the types of information maintained.

Relationship Between XEVMPD and EudraVigilance

XEVMPD and EudraVigilance are closely connected.

When adverse reaction reports are submitted, product information plays an important role in ensuring that cases are correctly associated with medicinal products.

Accurate product information supports:

• Case processing
• Signal detection
• Aggregate reporting
• Safety surveillance
• Regulatory analysis

Poor product data quality may affect downstream pharmacovigilance activities.

For an overview of EudraVigilance see:

[[what-is-eudravigilance]]

Why Product Data Quality Matters

Pharmacovigilance systems depend on accurate data.

Errors in medicinal product information may contribute to:

• Reporting inconsistencies
• Duplicate records
• Analytical limitations
• Signal detection challenges
• Regulatory concerns

Data quality issues often become visible only after they have already affected other processes.

Consequently, proactive governance is important.

Marketing Authorisation Holder Responsibilities

Marketing Authorisation Holders are responsible for maintaining accurate product information within applicable regulatory systems.

Responsibilities may include:

• Initial submissions
• Product updates
• Change management
• Data quality activities
• Regulatory maintenance

Organisations should have procedures describing how product information is governed and maintained.

Product Lifecycle Management

Product information changes throughout the lifecycle of a medicinal product.

Examples include:

• New authorisations
• Variations
• Withdrawals
• Name changes
• Manufacturing changes
• Administrative updates

Effective lifecycle management helps ensure that regulatory systems remain accurate and up to date.

Common Data Quality Challenges

Maintaining high-quality product information can be difficult.

Common challenges include:

• Incomplete records
• Inconsistent naming conventions
• Delayed updates
• Duplicate entries
• Governance gaps
• Ownership uncertainty

These issues may increase regulatory risk and reduce confidence in downstream analyses.

XEVMPD and Signal Detection

Although signal detection activities are generally associated with EVDAS, product information quality remains important.

Signal detection relies upon accurate product identification.

Poor product data may affect:

• Case grouping
• Trend analysis
• Signal evaluation
• Data interpretation

Consequently, product data quality indirectly supports signal management activities.

For additional information see:

[[evdas-and-signal-detection]]

QPPV Oversight

The QPPV is not usually responsible for maintaining XEVMPD records personally.

However, regulators generally expect the QPPV to understand:

• How product data are maintained
• Governance arrangements
• Data quality controls
• Compliance risks
• Escalation pathways

The QPPV should have confidence that medicinal product information is appropriately governed.

Inspection Perspective

Inspectors may review product data governance as part of broader pharmacovigilance system assessments.

Inspection activities may include review of:

• Governance structures
• Responsibilities
• Change control processes
• Data quality procedures
• Compliance monitoring activities

Inspectors are generally interested in whether organisations can demonstrate effective control over product information.

Common Inspection Findings

Observed deficiencies may include:

• Incomplete product records
• Delayed updates
• Poor governance controls
• Unclear responsibilities
• Inadequate quality oversight
• Weak documentation practices

Many findings arise because product data management is viewed as an administrative activity rather than a pharmacovigilance enabler.

XEVMPD and the Future of IDMP

The future of medicinal product data management within Europe is closely linked to the Identification of Medicinal Products (IDMP) standards.

IDMP aims to improve:

• Data standardisation
• Product identification
• Regulatory interoperability
• Data quality

As regulatory systems evolve, organisations will increasingly need to understand the relationship between existing XEVMPD processes and future IDMP requirements.

Practical Considerations for Organisations

Effective product data governance commonly includes:

• Defined ownership
• Change control procedures
• Data quality reviews
• Periodic reconciliations
• Compliance monitoring
• Training programmes

These controls help maintain confidence in medicinal product information and support wider pharmacovigilance activities.

Key Takeaways

• XEVMPD is the European medicinal product dictionary.
• It supports EudraVigilance and wider pharmacovigilance activities.
• Accurate product information is essential for effective safety surveillance.
• Product data quality influences reporting, signal detection and regulatory analysis.
• QPPVs are expected to understand governance arrangements relating to medicinal product data.
• Product data governance may be reviewed during inspections.
• XEVMPD is expected to evolve alongside broader IDMP initiatives.

References

1. Regulation (EC) No 726/2004.
2. Directive 2001/83/EC.
3. Commission Implementing Regulation (EU) No 520/2012.
4. EMA XEVMPD Guidance Documents.
5. EMA EudraVigilance Documentation.
6. GVP Module I – Pharmacovigilance Systems and Their Quality Systems.
7. GVP Module II – Pharmacovigilance System Master File.
8. ISO Identification of Medicinal Products (IDMP) Standards.